Lysophosphatidylcholine Molecular Species in Low Density Lipoprotein of Type 2 Diabetes

To reveal the importance of lysoposphatidyicholine (LPC) in patients with Type 2 diabetes (DM), LPC in low density lipoprotein (LDL) was determined by high performance liquid chromatography in 38 patients with Type 2 DM and 31 age and sex-matched non-diabetic controls. Stearoyl LPC (SLPC) and palmitoyl LPC (PLPC) were detected in LDL. The contents of both LPCs per gram protein in LDL were increased in diabetic patients compared with the non-diabetics (1.99 ± 0.94 mg SLPC and 3.02 ± 1.81 mg PLPC vs 1.47 ± 0.57 mg SLPC and 2.30 ± 0.83 mg PLPC, mean ± SD, p < 0.01 and p < 0.05, respectively). PLPC showed a weak correlation with the levels of fasting plasma glucose (FPG) and HbA1c (r = 0.27 and r = 0.33, p < 0.05 and p < 0.01, respectively). The diabetic patients with macroangiopathy showed higher levels of PLPC per gram protein compared to those without macroangiopathy (4.60 ± 2.61 mg vs 2.53 ± 1.15 mg, respectively, p < 0.05). The LPC molecular species may participate in the atherogenicity of LDL in patients with Type 2 diabetes.

Key words

Lysophosphatidylcholine - Low Density Lipoprotein - Type 2 DM